GlaxoSmithKline plc (GSKN) — Free Cash Flow Generation Index
GlaxoSmithKline plc (GSKN) has a Free Cash Flow Generation Index of 0.60x as of September 2025. Free cash flow of MX$1.34 Billion represents 1% of operating cash flow (MX$2.22 Billion). Explore GlaxoSmithKline plc capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
GlaxoSmithKline plc Free Cash Flow Generation Index (2013–2024)
Historical FCF Generation Index trend for GlaxoSmithKline plc across 12 annual periods. For the full cash flow conversion analysis, see GSKN operating cash flow.
Annual Free Cash Flow Generation for GlaxoSmithKline plc (2013–2024)
Year-by-year Free Cash Flow Generation Index for GlaxoSmithKline plc. Check GlaxoSmithKline plc (GSKN) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (MXN) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.55x | MX$3.57 Billion | MX$6.55 Billion | MX$2.98 Billion | ▼ -5.7% |
| 2023 | 0.58x | MX$3.17 Billion | MX$5.48 Billion | MX$2.31 Billion | ▼ -16.9% |
| 2022 | 0.69x | MX$5.14 Billion | MX$7.40 Billion | MX$1.14 Billion | ▲ +10.1% |
| 2021 | 0.63x | MX$5.02 Billion | MX$7.95 Billion | MX$950.00 Million | ▼ -14.1% |
| 2020 | 0.73x | MX$6.20 Billion | MX$8.44 Billion | MX$989.00 Million | ▲ +0.6% |
| 2019 | 0.73x | MX$5.86 Billion | MX$8.02 Billion | MX$1.26 Billion | ▼ -7.2% |
| 2018 | 0.79x | MX$6.62 Billion | MX$8.42 Billion | MX$1.34 Billion | ▲ +15.4% |
| 2017 | 0.68x | MX$4.72 Billion | MX$6.92 Billion | MX$1.54 Billion | ▼ -49.9% |
| 2016 | 1.36x | MX$8.85 Billion | MX$6.50 Billion | MX$2.35 Billion | ▼ -11.4% |
| 2015 | 1.54x | MX$3.95 Billion | MX$2.57 Billion | MX$1.38 Billion | ▲ +25.0% |
| 2014 | 1.23x | MX$6.36 Billion | MX$5.18 Billion | MX$1.19 Billion | ▲ +5.6% |
| 2013 | 1.16x | MX$8.41 Billion | MX$7.22 Billion | MX$1.19 Billion | — |